vs
GENCOR INDUSTRIES INC（GENC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是GENCOR INDUSTRIES INC的1.3倍（$30.3M vs $23.6M），GENCOR INDUSTRIES INC净利率更高（14.6% vs -221.3%，领先235.9%），REGENXBIO Inc.同比增速更快（43.0% vs -25.0%），GENCOR INDUSTRIES INC自由现金流更多（$10.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -23.9%）
Gencor Industries Inc是一家重型基建设备制造商，主打沥青生产装置、热力燃烧系统及配套道路施工机械，主要服务北美及全球建筑市场，客户涵盖公共基建项目方和私营建筑运营商。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GENC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.6M
营收增速更快
RGNX
高出68.0%
-25.0%
净利率更高
GENC
高出235.9%
-221.3%
自由现金流更多
GENC
多$62.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-23.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.6M | $30.3M |
| 净利润 | $3.4M | $-67.1M |
| 毛利率 | 28.7% | — |
| 营业利润率 | 13.2% | -190.0% |
| 净利率 | 14.6% | -221.3% |
| 营收同比 | -25.0% | 43.0% |
| 净利润同比 | -9.8% | -31.2% |
| 每股收益（稀释后） | $0.23 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GENCRGNX
| Q4 25 | $23.6M | $30.3M | ||
| Q3 25 | $18.8M | $29.7M | ||
| Q2 25 | $27.0M | $21.4M | ||
| Q1 25 | $38.2M | $89.0M | ||
| Q4 24 | $31.4M | $21.2M | ||
| Q3 24 | $20.9M | $24.2M | ||
| Q2 24 | $25.6M | $22.3M | ||
| Q1 24 | $40.7M | $15.6M |
净利润GENCRGNX
| Q4 25 | $3.4M | $-67.1M | ||
| Q3 25 | $1.9M | $-61.9M | ||
| Q2 25 | $3.8M | $-70.9M | ||
| Q1 25 | $6.1M | $6.1M | ||
| Q4 24 | $3.8M | $-51.2M | ||
| Q3 24 | $1.5M | $-59.6M | ||
| Q2 24 | $2.6M | $-53.0M | ||
| Q1 24 | $6.2M | $-63.3M |
毛利率GENCRGNX
| Q4 25 | 28.7% | — | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 29.7% | — | ||
| Q4 24 | 27.6% | 70.2% | ||
| Q3 24 | 25.6% | 48.8% | ||
| Q2 24 | 23.9% | 52.5% | ||
| Q1 24 | 30.3% | 72.6% |
营业利润率GENCRGNX
| Q4 25 | 13.2% | -190.0% | ||
| Q3 25 | -1.2% | -176.3% | ||
| Q2 25 | 11.6% | -296.3% | ||
| Q1 25 | 17.0% | 13.6% | ||
| Q4 24 | 14.7% | -242.1% | ||
| Q3 24 | 5.9% | -256.6% | ||
| Q2 24 | 7.8% | -251.3% | ||
| Q1 24 | 17.4% | -408.8% |
净利率GENCRGNX
| Q4 25 | 14.6% | -221.3% | ||
| Q3 25 | 10.2% | -208.3% | ||
| Q2 25 | 14.2% | -331.8% | ||
| Q1 25 | 16.0% | 6.8% | ||
| Q4 24 | 12.1% | -241.3% | ||
| Q3 24 | 6.9% | -246.3% | ||
| Q2 24 | 10.0% | -237.7% | ||
| Q1 24 | 15.3% | -405.4% |
每股收益（稀释后）GENCRGNX
| Q4 25 | $0.23 | $-1.30 | ||
| Q3 25 | $0.13 | $-1.20 | ||
| Q2 25 | $0.26 | $-1.38 | ||
| Q1 25 | $0.42 | $0.12 | ||
| Q4 24 | $0.26 | $-0.99 | ||
| Q3 24 | $0.10 | $-1.17 | ||
| Q2 24 | $0.17 | $-1.05 | ||
| Q1 24 | $0.42 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $147.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $215.2M | $102.7M |
| 总资产 | $228.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GENCRGNX
| Q4 25 | $147.7M | $230.1M | ||
| Q3 25 | $136.3M | $274.2M | ||
| Q2 25 | $136.0M | $323.3M | ||
| Q1 25 | $143.7M | $267.9M | ||
| Q4 24 | $130.1M | $234.7M | ||
| Q3 24 | $115.4M | $255.5M | ||
| Q2 24 | $116.6M | $290.4M | ||
| Q1 24 | $117.1M | $338.7M |
总债务GENCRGNX
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GENCRGNX
| Q4 25 | $215.2M | $102.7M | ||
| Q3 25 | $211.8M | $161.5M | ||
| Q2 25 | $209.9M | $213.7M | ||
| Q1 25 | $206.1M | $274.2M | ||
| Q4 24 | $200.0M | $259.7M | ||
| Q3 24 | $196.1M | $301.4M | ||
| Q2 24 | $194.7M | $348.3M | ||
| Q1 24 | $192.1M | $390.7M |
总资产GENCRGNX
| Q4 25 | $228.9M | $453.0M | ||
| Q3 25 | $222.6M | $525.2M | ||
| Q2 25 | $220.2M | $581.0M | ||
| Q1 25 | $223.9M | $490.9M | ||
| Q4 24 | $218.2M | $466.0M | ||
| Q3 24 | $208.1M | $519.1M | ||
| Q2 24 | $201.8M | $569.4M | ||
| Q1 24 | $206.0M | $629.2M |
负债/权益比GENCRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $10.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 43.0% | -174.0% |
| 资本支出强度资本支出/营收 | 4.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.23× | — |
| 过去12个月自由现金流最近4个季度 | $-3.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GENCRGNX
| Q4 25 | $11.1M | $-52.3M | ||
| Q3 25 | $-275.0K | $-56.0M | ||
| Q2 25 | $-23.9M | $-49.3M | ||
| Q1 25 | $12.4M | $33.6M | ||
| Q4 24 | $14.8M | $-31.6M | ||
| Q3 24 | $-3.2M | $-40.5M | ||
| Q2 24 | $-1.0M | $-45.5M | ||
| Q1 24 | $11.7M | $-55.5M |
自由现金流GENCRGNX
| Q4 25 | $10.1M | $-52.8M | ||
| Q3 25 | $-1.3M | $-56.5M | ||
| Q2 25 | $-24.4M | $-49.7M | ||
| Q1 25 | $12.3M | $32.6M | ||
| Q4 24 | $14.5M | $-32.7M | ||
| Q3 24 | $-3.3M | $-40.9M | ||
| Q2 24 | $-1.4M | $-46.0M | ||
| Q1 24 | $11.7M | $-56.0M |
自由现金流率GENCRGNX
| Q4 25 | 43.0% | -174.0% | ||
| Q3 25 | -6.8% | -189.9% | ||
| Q2 25 | -90.4% | -232.8% | ||
| Q1 25 | 32.2% | 36.6% | ||
| Q4 24 | 46.1% | -154.2% | ||
| Q3 24 | -15.8% | -168.9% | ||
| Q2 24 | -5.6% | -206.2% | ||
| Q1 24 | 28.7% | -358.5% |
资本支出强度GENCRGNX
| Q4 25 | 4.1% | 1.7% | ||
| Q3 25 | 5.4% | 1.7% | ||
| Q2 25 | 1.8% | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 1.0% | 5.1% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 1.5% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率GENCRGNX
| Q4 25 | 3.23× | — | ||
| Q3 25 | -0.14× | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | 2.04× | 5.53× | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | -2.22× | — | ||
| Q2 24 | -0.41× | — | ||
| Q1 24 | 1.87× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GENC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
